Seer Sees Revenue Target of $17M-$18M for 2025 Amid Macro Challenges and New Product Launch

Seer Inc. reiterates its revenue target of $17M-$18M for 2025, despite macroeconomic headwinds. The company launched Proteograph ONE in Q2 2025, a pivotal quarter that saw the acceleration of commercial and product milestones, and the validation of its platform.

Seer Inc. (Nasdaq: SEER) has reiterated its revenue target of $17 million to $18 million for the full year 2025, despite the challenging macroeconomic environment. The company reported strong financial results for the second quarter ended June 30, 2025, driven by increased product sales and service revenue [1].

The quarter saw the launch of the high-throughput Proteograph ONE assay and SP200 automation instrument, which significantly enhanced the scalability and efficiency of the company's platform. Additionally, Seer announced a collaboration with Korea University to launch a 20,000-sample population-scale proteomics study utilizing the Proteograph ONE assay to develop AI-driven diagnostics for cancers in young adults [1].

Despite the robust performance, Seer reported a net loss of $19.4 million for the second quarter, compared to $22.9 million for the same period last year. The decrease in operating expenses, primarily driven by a decrease in stock-based compensation, contributed to the improved financial results [1].

The company expects full-year 2025 revenue to be in the range of $17 million to $18 million, representing growth of 24% at the midpoint over full year 2024. Seer will host a conference call to discuss the second quarter 2025 financial results on Wednesday, August 6, 2025, at 1:30 pm Pacific Time / 4:30 pm Eastern Time [1].

References:
[1] https://finance.yahoo.com/news/seer-reports-second-quarter-2025-200500400.html